XENT Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 saus. 1970 @ 03:00):

Stats
Šios dienos apimtis	0.00
Vidutinė apimtis	438 704
Rinkos kapitalizacija	0.00
EPS	$-0.850 ( 2022-05-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.54
ATR14	$0.137 (0.49%)

Insider Trading

Date	Person	Action	Amount	type
2022-05-13	Meier Richard A	Sell	57 230	Common Stock
2022-05-13	Meier Richard A	Sell	65 759	Common Stock
2022-05-13	Meier Richard A	Sell	40 607	Common Stock
2022-05-13	Meier Richard A	Sell	34 000	Stock Options (Right to buy)
2022-05-13	Meier Richard A	Sell	74 852	Stock Options (Right to buy)

INSIDER POWER
-100.00
Last 98 transactions
Buy: 482 629 \| Sell: 874 745

Tūris Koreliacija

Ilgas: 0.54 (weak)

Trumpas: 0.61 (weak)

Signal:(64.961) Neutral

Intersect Ent Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
GLLI	0.937
ACAB	0.933
FEXD	0.929
APMI	0.929
FNVT	0.929
AVAC	0.928
CBRG	0.926
CIIG	0.925
BRIV	0.923
ALSA	0.921

10 Labiausiai neigiamai susiję koreliacijos
EVLO	-0.925
NCBS	-0.923
IRBT	-0.922
CREG	-0.92
DRUG	-0.917
ATAI	-0.916
CRON	-0.913
ARQQ	-0.912
BLU	-0.911
VFF	-0.91

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Intersect Ent Inc Koreliacija - Valiuta/Žaliavos

0.00
( neutral )

0.63
( weak )

0.00
( neutral )

0.21
( neutral )

0.10
( neutral )

0.05
( neutral )

Intersect Ent Inc Finansinės ataskaitos

Annual	2021
Pajamos:	$106.75M
Bruto pelnas:	$76.74M (71.89 %)
EPS:	$-4.80

FY	2021
Pajamos:	$106.75M
Bruto pelnas:	$76.74M (71.89 %)
EPS:	$-4.80

FY	2020
Pajamos:	$80.55M
Bruto pelnas:	$50.25M (62.38 %)
EPS:	$-2.22

FY	2019
Pajamos:	$109.14M
Bruto pelnas:	$87.37M (80.05 %)
EPS:	$-1.370

Financial Reports:

No articles found.

Intersect Ent Inc

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.